Weaker intracellular cleanup hinders the removal of senescent cells in mice
A peer-reviewed study connects declining intracellular protein cleanup with impaired immune removal of senescent cells. Signals from those cells suppress the same cleanup pathway in macrophages, which then engulf them less effectively. Aged mice had fewer senescent cells following pathway activation, and a mouse lung-fibrosis model showed reduced disease severity. Clinical benefit in humans has not been established.
A single peer-reviewed study links senescent-cell persistence to weaker protein cleanup inside cells. Senescent cells have entered a state in which division has durably stopped. Reduced cleanup did not initiate it by itself; it altered cells already in that state. Their secreted signals increased senescence in neighbouring cells and suppressed the cleanup pathway in macrophages. These immune cells became less able to engulf senescent cells, connecting their accumulation with a decline in clearance capacity.[1]
LAMP2A loss delayed resolution during wound healing
Chaperone-mediated autophagy is a selective protein disposal pathway: it sends proteins inside the cell to lysosomes, where they are broken down. LAMP2A, a receptor in the lysosomal membrane, is essential to this transport. Researchers combined fibroblast models, young and aged mice, macrophage-targeted genetic interventions and human lung data. When macrophages lost LAMP2A, more senescent cells accumulated and their removal during wound healing took longer. The experiments examined the secreted mixture from senescent cells together with the macrophages’ own processing machinery, rather than treating them as separate aging measures.[1]
Activating cleanup reduced cell burden in aged mice
After drug activation of the pathway, aged mice carried fewer senescent cells. A separate mouse model of lung fibrosis induced with bleomycin also showed less severe disease. Human lung associations relied on indicators of autophagy activity, without an experimental treatment comparison. Much of the cell work used fibroblasts with palbociclib-induced senescence. The LysM-Cre genetic system can affect monocytes and granulocytes as well as macrophages, limiting attribution to macrophages alone. The results establish cell and animal-model findings; human safety, dosing, long-term effects and clinical benefit were not evaluated.[1]
